Search - tctmd.com

Displaying 21 - 40 of 69

Sort: Relevancy | Date

Impact of Heart Failure Management Using Thoracic Fluid Monitoring From A Novel Wearable Sensor: Results of the Benefits of Microcor (μCor™) in Ambulatory Heart Failure (BMAD) Trial

Presentation ACC 2023

Impact of Heart Failure Management Using Thoracic Fluid Monitoring From A Novel Wearable Sensor: Results of the Benefits of Microcor (μCor™) in Ambulatory Heart Failure (BMAD) Trial

Presenter: John P. Boehmer

March 05, 2023

STOP-CA: Atorvastatin Curbs Heart Function Decline During Chemotherapy

News Conference News ACC 2023

STOP-CA: Atorvastatin Curbs Heart Function Decline During Chemotherapy

March 04, 2023

What’s Going to Be Hot at ACC/WCC 2023?

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

February 27, 2023

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

News Conference News ACC 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

April 08, 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

News Conference News ACC 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

April 08, 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

April 07, 2022

POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery

News Conference News ACC 2022

POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery

April 06, 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Presentation ACC 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Presenter: Florian Rader

April 04, 2022

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

Presentation ACC 2022

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

Presenter: Michael Felker

April 04, 2022

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Presentation ACC 2022

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Presenter: Tariq Ahmad

April 04, 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

News Conference News ACC 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

April 03, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

CHAP: Better Blood Pressure Control, Better Pregnancy Outcomes

News Conference News ACC 2022

CHAP: Better Blood Pressure Control, Better Pregnancy Outcomes

Michael O'Riordan

April 02, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

News Conference News ACC 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Michael O'Riordan

May 18, 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

May 18, 2021

RAFT-AF: No Benefit of AF Ablation for Heart Failure Patients

News Conference News ACC 2021

RAFT-AF: No Benefit of AF Ablation for Heart Failure Patients

May 17, 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

News Conference News ACC 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

May 16, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.